OXYGEN
24/08/2006, 08h47
Le patron de GSK, le français JP Garnier, l'annonce : du groupe des 15 firmes constituant "big pharma" seulement quelques unes d'entre elles survivront à la spirale de l'augmentation des coûts de développement de nouveaux médicaments. Peu de firmes ont les reins assez solides pour être capable d'investir en R&D pour développer un nouveau médicament. Il dit aussi que certains on trop investi en "marketing et ventes" et pas assez en R&D. Il annonce "de fait" des séries de fusions-acquisitions entre les sociétés pharmaceutiques dont celles de Big Pharma.
GSK boss predicts demise of most ‘big pharma’ rivals
By Amanda Andrews
ONLY a “handful” of the world’s top 15 drug makers will survive the industry’s spiralling research and development costs, J. P. Garnier, the chief executive of GlaxoSmithKline, predicted yesterday.
In an interview with Germany’s Manager magazine, the head of the world’s second- largest drugs group said that a significant number of the leading pharmaceutical companies invested too heavily in advertising and marketing at the expense of R&D and production.
“From 15 pharmaceutical companies that are important today, only a handful will probably survive,” Dr Garnier said.
“Hardly any of the large companies are in a position right now to invest enough money into research. A medium-sized company will hardly be able to spend enough on R&D.”
Peter Cartwright, a Williams de Broë analyst, said: “Companies are unlikely to close but will probably end up merging.”
Times on line
NDLR : il faut rapprocher cette déclaration de la situation des grands de big pharma qui sont en convalescence comme MSD, Pfizer, les renaissants comme Wyeth, Schering Plough ... et ceux qui vont mal comme Lilly, BMS,... Pour connaître les survivants il faut tenir compte que certains disposent de beaucoup de réserves pour racheter les autres. Fameux poker en perpective.
...
GSK boss predicts demise of most ‘big pharma’ rivals
By Amanda Andrews
ONLY a “handful” of the world’s top 15 drug makers will survive the industry’s spiralling research and development costs, J. P. Garnier, the chief executive of GlaxoSmithKline, predicted yesterday.
In an interview with Germany’s Manager magazine, the head of the world’s second- largest drugs group said that a significant number of the leading pharmaceutical companies invested too heavily in advertising and marketing at the expense of R&D and production.
“From 15 pharmaceutical companies that are important today, only a handful will probably survive,” Dr Garnier said.
“Hardly any of the large companies are in a position right now to invest enough money into research. A medium-sized company will hardly be able to spend enough on R&D.”
Peter Cartwright, a Williams de Broë analyst, said: “Companies are unlikely to close but will probably end up merging.”
Times on line
NDLR : il faut rapprocher cette déclaration de la situation des grands de big pharma qui sont en convalescence comme MSD, Pfizer, les renaissants comme Wyeth, Schering Plough ... et ceux qui vont mal comme Lilly, BMS,... Pour connaître les survivants il faut tenir compte que certains disposent de beaucoup de réserves pour racheter les autres. Fameux poker en perpective.
...